CASI Pharmaceuticals Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CASI Nasdaq 2836 http://www.casipharmaceuticals.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CASI Pharmaceuticals Inc

A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last year - Feb 6th, 2023 1:07 pm
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China - Jan 6th, 2023 1:42 pm
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA - Jan 6th, 2023 12:00 pm
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION - Dec 15th, 2022 12:00 pm
CASI Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations - Nov 17th, 2022 10:39 am
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates - Nov 14th, 2022 1:15 pm
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS - Nov 14th, 2022 12:00 pm
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET - Sep 23rd, 2022 11:00 am
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA - Sep 7th, 2022 11:00 am
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates - Aug 12th, 2022 12:35 pm
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS - Aug 12th, 2022 11:00 am
Even after rising 58% this past week, CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still down 88% over the past three years - Aug 12th, 2022 10:25 am
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 - Aug 5th, 2022 12:38 pm
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION - Jul 8th, 2022 11:00 am
CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT - May 26th, 2022 8:30 pm
A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 10% last year - May 25th, 2022 11:53 am
CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD - May 24th, 2022 11:00 am
CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2022 12:15 pm
Edited Transcript of CASI.OQ earnings conference call or presentation 12-May-22 12:00pm GMT - May 12th, 2022 12:00 pm
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - May 12th, 2022 11:00 am